HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Bolsters Botox Business With Record-Setting Korean Deal

This article was originally published in PharmAsia News

Executive Summary

In the largest licensing deal ever signed by a Korean health care company, Medy-Tox teams up with Allergan for next-generation neurotoxin products that could help Allergan protect its lead as new competitors like J&J look to enter the market.

You may also be interested in...

Allergan Hopes To Shed Excess Fat As It Grows Other Franchises

The Irvine, Calif.-based company reported full-year results on Feb. 5 that highlighted the growth of its Botox business to several new indications.

Allergan Buys MAP To Chart Migraine Franchise Growth

Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.

Botox Adds Therapeutic Indication For Idiopathic Overactive Bladder

The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts